Arnold, A. et al. Hormonal regulation of biomineralization. Nat. Rev. Endocrinol. 17, 261–275 (2021).
Hasegawa, T. Ultrastructure and organic perform of matrix vesicles in bone mineralization. Histochem. Cell Biol. 149, 289–304 (2018).
Azoidis, I., Cox, S. C. & Davies, O. G. The function of extracellular vesicles in biomineralisation: present perspective and software in regenerative drugs. J. Tissue Eng. 9, 2041731418810130 (2018).
Golub, E. E. Function of matrix vesicles in biomineralization. Biochim. Biophys. Acta 1790, 1592–1598 (2009).
Orimo, H. The mechanism of mineralization and the function of alkaline phosphatase in well being and illness. J. Nippon Med. Sch. 77, 4–12 (2010).
Ali, S. Y., Sajdera, S. W. & Anderson, H. C. Isolation and characterization of calcifying matrix vesicles from epiphyseal cartilage. Proc. Natl Acad. Sci. USA 67, 1513–1520 (1970).
Morris, D. C., Masuhara, Ok., Takaoka, Ok., Ono, Ok. & Anderson, H. C. Immunolocalization of alkaline phosphatase in osteoblasts and matrix vesicles of human fetal bone. Bone Min. 19, 287–298 (1992).
Anderson, H. C. The function of matrix vesicles in physiological and pathological calcification. Curr. Opin. Orthop. 18, 428–433 (2007).
Anderson, H. C. Molecular biology of matrix vesicles. Clin. Orthop. Relat. Res. 314, 266–280 (1995).
Asmussen, N., Lin, Z., McClure, M. J., Schwartz, Z. & Boyan, B. D. Regulation of extracellular matrix vesicles through fast responses to steroid hormones throughout endochondral bone formation. Steroids 142, 43–47 (2019).
Shapiro, I. M., Landis, W. J. & Risbud, M. V. Matrix vesicles: are they anchored exosomes? Bone 79, 29–36 (2015).
Masaoutis, C. & Theocharis, S. The function of exosomes in bone reworking: implications for bone physiology and illness. Dis. Markers 2019, 9417914 (2019).
Bonucci, E. Bone mineralization. Entrance. Biosci. 17, 100–128 (2012).
Balcerzak, M. et al. The roles of annexins and alkaline phosphatase in mineralization course of. Acta Biochim. Pol. 50, 1019–1038 (2003).
Kirsch, T., Harrison, G., Golub, E. E. & Nah, H. D. The roles of annexins and kinds II and X collagen in matrix vesicle-mediated mineralization of progress plate cartilage. J. Biol. Chem. 275, 35577–35583 (2000).
Guicheux, J. et al. A novel in vitro tradition system for evaluation of purposeful function of phosphate transport in endochondral ossification. Bone 27, 69–74 (2000).
Yoshiko, Y., Candeliere, G. A., Maeda, N. & Aubin, J. E. Osteoblast autonomous Pi regulation through Pit1 performs a task in bone mineralization. Mol. Cell Biol. 27, 4465–4474 (2007).
Millan, J. L. The function of phosphatases within the initiation of skeletal mineralization. Calcif. Tissue Int. 93, 299–306 (2013).
Addison, W. N., Azari, F., Sorensen, E. S., Kaartinen, M. T. & McKee, M. D. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase exercise. J. Biol. Chem. 282, 15872–15883 (2007).
Terkeltaub, R. A. Inorganic pyrophosphate technology and disposition in pathophysiology. Am. J. Physiol. Cell Physiol. 281, C1–C11 (2001).
Brylka, L. & Jahnen-Dechent, W. The function of fetuin-A in physiological and pathological mineralization. Calcif. Tissue Int. 93, 355–364 (2013).
Zoch, M. L., Clemens, T. L. & Riddle, R. C. New insights into the biology of osteocalcin. Bone 82, 42–49 (2016).
Grynpas, M. D., Chachra, D. & Limeback, H. in The Osteoporosis Primer Vol. 23 318-330 (Cambridge College Press, 2000).
Boivin, G., Chavassieux, P., Chapuy, M. C., Baud, C. A. & Meunier, P. J. Skeletal fluorosis: histomorphometric evaluation of bone modifications and bone fluoride content material in 29 sufferers. Bone 10, 89–99 (1989).
Grynpas, M. D. Fluoride results on bone crystals. J. Bone Min. Res. 5 (Suppl. 1), S169–S175 (1990).
Moreno, E. C., Kresak, M. & Zahradnik, R. T. Physicochemical points of fluoride-apatite programs related to the examine of dental caries. Caries Res. 11 (Suppl. 1), 142–171 (1977).
Grynpas, M. D., Patterson-Allen, P. & Simmons, D. J. The modifications in high quality of mandibular bone mineral in in any other case completely immobilized rhesus monkeys. Calcif. Tissue Int. 39, 57–62 (1986).
Chavassieux, P., Seeman, E. & Delmas, P. D. Insights into materials and structural foundation of bone fragility from illnesses related to fractures: how determinants of the biomechanical properties of bone are compromised by illness. Endocr. Rev. 28, 151–164 (2007).
Whyte, M. P. Hypophosphatasia-aetiology, nosology, pathogenesis, analysis and therapy. Nat. Rev. Endocrinol. 12, 233–246 (2016).
Weiss, M. J. et al. A missense mutation within the human liver/bone/kidney alkaline phosphatase gene inflicting a deadly type of hypophosphatasia. Proc. Natl Acad. Sci. USA 85, 7666–7669 (1988).
Weiss, M. J. et al. Construction of the human liver/bone/kidney alkaline phosphatase gene. J. Biol. Chem. 263, 12002–12010 (1988).
Millan, J. L. & Whyte, M. P. Alkaline phosphatase and hypophosphatasia. Calcif. Tissue Int. 98, 398–416 (2016).
Whyte, M. P. Hypophosphatasia: enzyme alternative remedy brings new alternatives and new challenges. J. Bone Min. Res. 32, 667–675 (2017).
Whyte, M. P. et al. Asfotase alfa remedy for youngsters with hypophosphatasia. JCI Perception 1, e85971 (2016).
Whyte, M. P., McAlister, W. H., Mumm, S. & Bierhals, A. J. No vascular calcification on cardiac computed tomography spanning asfotase alfa therapy for an aged lady with hypophosphatasia. Bone 122, 231–236 (2019).
Whyte, M. P. et al. Asfotase alfa for infants and younger youngsters with hypophosphatasia: 7 yr outcomes of a single-arm, open-label, section 2 extension trial. Lancet Diabetes Endocrinol. 7, 93–105 (2019).
Mornet, E. Hypophosphatasia: the mutations within the tissue-nonspecific alkaline phosphatase gene. Hum. Mutat. 15, 309–315 (2020).
Whyte, M. P. et al. Hypophosphatasia: validation and enlargement of the medical nosology for youngsters from 25 years expertise with 173 pediatric sufferers. Bone 75, 229–239 (2015).
Whyte, M. P. et al. Enzyme-replacement remedy in life-threatening hypophosphatasia. N. Engl. J. Med. 366, 904–913 (2012).
Guanabens, N. et al. Calcific periarthritis as the one medical manifestation of hypophosphatasia in middle-aged sisters. J. Bone Min. Res. 29, 929–934 (2014).
Camacho, P. M. et al. Grownup hypophosphatasia handled with teriparatide: report of two sufferers and overview of the literature. Endocr. Pract. 22, 941–950 (2016).
Sutton, R. A., Mumm, S., Coburn, S. P., Ericson, Ok. L. & Whyte, M. P. “Atypical femoral fractures” throughout bisphosphonate publicity in grownup hypophosphatasia. J. Bone Min. Res. 27, 987–994 (2012).
Sobel, E. H., Clark, L. C. Jr, Fox, R. P. & Robinow, M. Rickets, deficiency of alkaline phosphatase exercise and untimely lack of tooth in childhood. Pediatrics 11, 309–322 (1953).
Ornoy, A., Adomian, G. E. & Rimoin, D. L. Histologic and ultrastructural research on the mineralization course of in hypophosphatasia. Am. J. Med. Genet. 22, 743–758 (1985).
Anderson, H. C., Hsu, H. H., Morris, D. C., Fedde, Ok. N. & Whyte, M. P. Matrix vesicles in osteomalacic hypophosphatasia bone include apatite-like mineral crystals. Am. J. Pathol. 151, 1555–1561 (1997).
McKenna, M. J., Martin-Grace, J., Crowley, R., Twomey, P. J. & Kilbane, M. T. Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate losing following whole parathyroidectomy. J. Bone Min. Metab. 37, 685–693 (2019).
Haffner, D. et al. Medical follow suggestions for the analysis and administration of X-linked hypophosphataemia. Nat. Rev. Nephrol. 15, 435–455 (2019).
Marcucci, G. et al. Phosphate losing issues in adults. Osteoporos. Int. 29, 2369–2387 (2018).
Manghat, P., Sodi, R. & Swaminathan, R. Phosphate homeostasis and issues. Ann. Clin. Biochem. 51, 631–656 (2014).
Shimada, T. et al. Focused ablation of Fgf23 demonstrates a vital physiological function of FGF23 in phosphate and vitamin D metabolism. J. Clin. Make investments. 113, 561–568 (2004).
Goretti Penido, M. & Alon, U. S. Phosphate homeostasis and its function in bone well being. Pediatr. Nephrol. 27, 2039–2048 (2012).
Tiosano, D. & Hochberg, Z. Hypophosphatemia: the frequent denominator of all rickets. J. Bone Min. Metab. 27, 392–401 (2009).
Beck-Nielsen, S. S. et al. FGF23 and its function in X-linked hypophosphatemia-related morbidity. Orphanet J. Uncommon Dis. 14, 58 (2019).
Bai, X. et al. CYP24 inhibition as a therapeutic goal in FGF23-mediated renal phosphate losing issues. J. Clin. Make investments. 126, 667–680 (2016).
Beck-Nielsen, S. S., Brock-Jacobsen, B., Gram, J., Brixen, Ok. & Jensen, T. Ok. Incidence and prevalence of dietary and hereditary rickets in southern Denmark. Eur. J. Endocrinol. 160, 491–497 (2009).
Liu, S., Guo, R. & Quarles, L. D. Cloning and characterization of the proximal murine Phex promoter. Endocrinology 142, 3987–3995 (2001).
Weng, C. et al. A de novo mosaic mutation of PHEX in a boy with hypophosphatemic rickets. J. Hum. Genet. 61, 223–227 (2016).
Whyte, M. P., Schranck, F. W. & Armamento-Villareal, R. X-linked hypophosphatemia: a seek for gender, race, anticipation, or dad or mum of origin results on illness expression in youngsters. J. Clin. Endocrinol. Metab. 81, 4075–4080 (1996).
Linglart, A. et al. Therapeutic administration of hypophosphatemic rickets from infancy to maturity. Endocr. Join. 3, R13–R30 (2014).
Alon, U. S. et al. Hypertension in hypophosphatemic rickets — function of secondary hyperparathyroidism. Pediatr. Nephrol. 18, 155–158 (2003).
Barros, N. M. et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine mannequin of X-linked hypophosphatemia. J. Bone Min. Res. 28, 688–699 (2013).
Addison, W. N., Masica, D. L., Grey, J. J. & McKee, M. D. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J. Bone Min. Res. 25, 695–705 (2010).
Murthy, A. S. X-linked hypophosphatemic rickets and craniosynostosis. J. Craniofac Surg. 20, 439–442 (2009).
Zivicnjak, M. et al. Age-related stature and linear physique segments in youngsters with X-linked hypophosphatemic rickets. Pediatr. Nephrol. 26, 223–231 (2011).
Carpenter, T. O., Imel, E. A., Holm, I. A., Jan de Beur, S. M. & Insogna, Ok. L. A clinician’s information to X-linked hypophosphatemia. J. Bone Min. Res. 26, 1381–1388 (2011).
Balsan, S. & Tieder, M. Linear progress in sufferers with hypophosphatemic vitamin D-resistant rickets: affect of therapy routine and parental top. J. Pediatr. 116, 365–371 (1990).
Chaussain-Miller, C. et al. Dental abnormalities in sufferers with familial hypophosphatemic vitamin D-resistant rickets: prevention by early therapy with 1-hydroxyvitamin D. J. Pediatr. 142, 324–331 (2003).
Biosse Duplan, M. et al. Phosphate and vitamin D forestall periodontitis in X-linked hypophosphatemia. J. Dent. Res. 96, 388–395 (2017).
Boukpessi, T. et al. Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone 95, 151–161 (2017).
Che, H. et al. Impaired high quality of life in adults with X-linked hypophosphatemia and skeletal signs. Eur. J. Endocrinol. 174, 325–333 (2016).
Faraji-Bellee, C. A. et al. Growth of enthesopathies and joint structural harm in a murine mannequin of X-linked hypophosphatemia. Entrance. Cell Dev. Biol. 8, 854 (2020).
Solar, G. E., Suer, O., Carpenter, T. O., Tan, C. D. & Li-Ng, M. Coronary heart failure in hypophosphatemic rickets: problems from high-dose phosphate remedy. Endocr. Pract. 19, e8–e11 (2013).
Currarino, G. Sagittal synostosis in X-linked hypophosphatemic rickets and associated illnesses. Pediatr. Radiol. 37, 805–812 (2007).
Glass, L. R., Dagi, T. F. & Dagi, L. R. Papilledema within the setting of x-linked hypophosphatemic rickets with craniosynostosis. Case Rep. Ophthalmol. 2, 376–381 (2011).
Rothenbuhler, A. et al. Excessive incidence of cranial synostosis and Chiari I malformation in youngsters with X-linked hypophosphatemic rickets (XLHR). J. Bone Min. Res. 34, 490–496 (2019).
Christie, P. T., Harding, B., Nesbit, M. A., Whyte, M. P. & Thakker, R. V. X-linked hypophosphatemia attributable to pseudoexons of the PHEX gene. J. Clin. Endocrinol. Metab. 86, 3840–3844 (2001).
Harrell, R. M., Lyles, Ok. W., Harrelson, J. M., Friedman, N. E. & Drezner, M. Ok. Therapeutic of bone illness in X-linked hypophosphatemic rickets/osteomalacia. Induction and upkeep with phosphorus and calcitriol. J. Clin. Make investments. 75, 1858–1868 (1985).
Imel, E. A. et al. Burosumab versus standard remedy in youngsters with X-linked hypophosphataemia: a randomised, active-controlled, open-label, section 3 trial. Lancet 393, 2416–2427 (2019).
Kinoshita, Y. & Fukumoto, S. X-Linked Hypophosphatemia and FGF23-Associated hypophosphatemic illnesses: prospect for brand new therapy. Endocr. Rev. 39, 274–291 (2018).
Huiming, Y. & Chaomin, W. Recombinant progress hormone remedy for X-linked hypophosphatemia in youngsters. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD004447.pub2 (2005).
Lecoq, A. L. et al. Hyperparathyroidism in Sufferers With X-Linked Hypophosphatemia. J. Bone Miner. Res. 35, 1263–1273 (2020).
Carpenter, T. O. The increasing household of hypophosphatemic syndromes. J. Bone Min. Metab. 30, 1–9 (2012).
Econs, M. J. & McEnery, P. T. Autosomal dominant hypophosphatemic rickets/osteomalacia: medical characterization of a novel renal phosphate-wasting dysfunction. J. Clin. Endocrinol. Metab. 82, 674–681 (1997).
Imel, E. A., Biggin, A., Schindeler, A. & Munns, C. F. FGF23, hypophosphatemia, and rising remedies. JBMR Plus 3, e10190 (2019).
Imel, E. A. et al. Iron modifies plasma FGF23 in another way in autosomal dominant hypophosphatemic rickets and wholesome people. J. Clin. Endocrinol. Metab. 96, 3541–3549 (2011).
Rutsch, F. et al. Mutations in ENPP1 are related to ‘idiopathic’ childish arterial calcification. Nat. Genet. 34, 379–381 (2003).
Levy-Litan, V. et al. Autosomal-recessive hypophosphatemic rickets is related to an inactivation mutation within the ENPP1 gene. Am. J. Hum. Genet. 86, 273–278 (2010).
Alon, U. S. Medical follow. Fibroblast progress issue (FGF)23: a brand new hormone. Eur. J. Pediatr. 170, 545–554 (2011).
Liu, T. et al. DMP1 ablation within the rabbit ends in mineralization defects and abnormalities in Haversian canal/osteon microarchitecture. J. Bone Min. Res. 34, 1115–1128 (2019).
Ferreira, C. R. et al. Potential phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI). Genet. Med. 23, 396–407 (2021).
Jaureguiberry, G., Carpenter, T. O., Forman, S., Juppner, H. & Bergwitz, C. A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in people identifies threonine 137 as an vital determinant of sodium-phosphate cotransport in NaPi-IIc. Am. J. Physiol. Ren. Physiol. 295, F371–F379 (2008).
Lorenz-Depiereux, B. et al. Hereditary hypophosphatemic rickets with hypercalciuria is attributable to mutations within the sodium-phosphate cotransporter gene SLC34A3. Am. J. Hum. Genet. 78, 193–201 (2006).
Bergwitz, C. & Miyamoto, Ok. I. Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, medical presentation, analysis and remedy. Pflug. Arch. 471, 149–163 (2019).
Haito-Sugino, S. et al. Processing and stability of sort IIc sodium-dependent phosphate cotransporter mutations in sufferers with hereditary hypophosphatemic rickets with hypercalciuria. Am. J. Physiol. Cell Physiol. 302, C1316–C1330 (2012).
Incorrect, O. M., Norden, A. G. & Feest, T. G. Dent’s illness; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone illness, progressive renal failure and a marked male predominance. QJM 87, 473–493 (1994).
Devuyst, O. & Thakker, R. V. Dent’s illness. Orphanet J. Uncommon Dis. 5, 28 (2010).
Hoopes, R. R. Jr. et al. Dent illness with mutations in OCRL1. Am. J. Hum. Genet. 76, 260–267 (2005).
Florenzano, P. et al. Tumor-induced osteomalacia. Calcif. Tissue Int. 108, 128–142 (2021).
Lee, J. C. et al. Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a big sequence of phosphaturic mesenchymal tumors. Mod. Pathol. 29, 1335–1346 (2016).
Endo, I. et al. Nationwide survey of fibroblast progress issue 23 (FGF23)-related hypophosphatemic illnesses in Japan: prevalence, biochemical knowledge and therapy. Endocr. J. 62, 811–816 (2015).
Jiang, Y. et al. Tumor-induced osteomalacia: an vital explanation for adult-onset hypophosphatemic osteomalacia in China: Report of 39 circumstances and overview of the literature. J. Bone Min. Res. 27, 1967–1975 (2012).
Minisola, S. et al. Tumour-induced osteomalacia. Nat. Rev. Dis. Prim. 3, 17044 (2017).
Wang, H. et al. Overexpression of fibroblast progress issue 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J. Bone Min. Res. 23, 939–948 (2008).
Brandi, M. L. et al. Challenges within the administration of tumor-induced osteomalacia (TIO). Bone 152, 116064 (2021).
Hartley, I. R. et al. Focused FGFR blockade for the therapy of tumor-induced osteomalacia. N. Engl. J. Med. 383, 1387–1389 (2020).
Ketteler, M., Gross, M. L. & Ritz, E. Calcification and cardiovascular issues in renal failure. Kidney Int. Suppl. https://doi.org/10.1111/j.1523-1755.2005.09428.x (2005).
Ramnitz, M. S., Gafni, R. I. & Collins, M. T. in GeneReviews Vol. NBK476672 (eds M. P. Adam et al.) (College of Washington, 2018).
Topaz, O. et al. Mutations in GALNT3, encoding a protein concerned in O-linked glycosylation, trigger familial tumoral calcinosis. Nat. Genet 36, 579–581 (2004).
Benet-Pages, A., Orlik, P., Strom, T. M. & Lorenz-Depiereux, B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 14, 385–390 (2005).
Ichikawa, S. et al. A homozygous missense mutation in human KLOTHO causes extreme tumoral calcinosis. J. Clin. Make investments. 117, 2684–2691 (2007).
Roberts, M. S. et al. Autoimmune hyperphosphatemic tumoral calcinosis in a affected person with FGF23 autoantibodies. J. Clin. Make investments. 128, 5368–5373 (2018).
Ramnitz, M. S., Gafni, R. I. & Collins, M. T. in GeneReviews Vol. NBK476672 (eds M. P. Adam et al.) (College of Washington, 2018).
Ramnitz, M. S. et al. Phenotypic and genotypic characterization and therapy of a cohort with familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome. J. Bone Min. Res. 31, 1845–1854 (2016).
Clerin, V. et al. Selective pharmacological inhibition of the sodium-dependent phosphate cotransporter NPT2a promotes phosphate excretion. J. Clin. Make investments. 130, 6510–6522 (2020).
Mannstadt, M. et al. Hypoparathyroidism. Nat. Rev. Dis. Prim. 3, 17055 (2017).
Bilezikian, J. P. et al. Administration of hypoparathyroidism: current and future. J. Clin. Endocrinol. Metab. 101, 2313–2324 (2016).
Underbjerg, L., Sikjaer, T. & Rejnmark, L. Lengthy-term problems in sufferers with hypoparathyroidism evaluated by biochemical findings: a case-control examine. J. Bone Min. Res. 33, 822–831 (2018).
Topaz, O. et al. A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. Am. J. Hum. Genet. 79, 759–764 (2006).
Levine, M. A. Prognosis and administration of vitamin D dependent rickets. Entrance. Pediatr. 8, 315 (2020).
Gara, N. et al. Renal tubular dysfunction throughout long-term adefovir or tenofovir remedy in persistent hepatitis B. Aliment. Pharmacol. Ther. 35, 1317–1325 (2012).
Gray, A. et al. Low-dose fluoride in postmenopausal ladies: a randomized managed trial. J. Clin. Endocrinol. Metab. 98, 2301–2307 (2013).
Jha, S. Ok., Mishra, V. Ok., Sharma, D. Ok. & Damodaran, T. Fluoride within the surroundings and its metabolism in people. Rev. Env. Contam. Toxicol. 211, 121–142 (2011).
Chen, J. et al. Coal utilization in China: environmental impacts and human well being. Env. Geochem. Well being 36, 735–753 (2014).
Majumdar, Ok. Ok. Well being influence of supplying protected ingesting water containing fluoride under permissible stage on flourosis sufferers in a fluoride-endemic rural space of West Bengal. Indian. J. Public Well being 55, 303–308 (2011).
Mousny, M. et al. Fluoride results on bone formation and mineralization are influenced by genetics. Bone 43, 1067–1074 (2008).
Pramanik, S. & Saha, D. The genetic affect in fluorosis. Env. Toxicol. Pharmacol. 56, 157–162 (2017).
Tamer, M. N. et al. Osteosclerosis because of endemic fluorosis. Sci. Complete. Env. 373, 43–48 (2007).
Pei, J. et al. Fluoride decreased osteoclastic bone resorption by means of the inhibition of NFATc1 gene expression. Env. Toxicol. 29, 588–595 (2014).
Liu, Q. et al. Evaluation of the function of insulin signaling in bone turnover induced by fluoride. Biol. Hint Elem. Res. 171, 380–390 (2016).
Teotia, S. P. S., Teotia, M., Singh, Ok. P. & India. in 4th Worldwide Workshop on Fluorosis Prevention and Defluoridation of Water (ed. Dahi, E.) (The Worldwide Society for Fluoride Analysis, 2004).
Khairnar, M. R., Dodamani, A. S., Jadhav, H. C., Naik, R. G. & Deshmukh, M. A. Mitigation of fluorosis — a overview. J. Clin. Diagn. Res. 9, ZE05–ZE09 (2015).
Mulay, S. R. & Anders, H. J. Crystallopathies. N. Engl. J. Med. 374, 2465–2476 (2016).
Munoz, L. E. et al. Neutrophil extracellular traps provoke gallstone formation. Immunity 51, 443–450.e444 (2019).
Chiti, F. & Dobson, C. M. Protein misfolding, amyloid formation, and human illness: a abstract of progress during the last decade. Annu. Rev. Biochem. 86, 27–68 (2017).
Mulay, S. R., Steiger, S., Shi, C. & Anders, H. J. A information to crystal-related and nano- or microparticle-related tissue responses. FEBS J. 287, 818–832 (2020).
Kzhyshkowska, J. et al. Macrophage responses to implants: prospects for personalised drugs. J. Leukoc. Biol. 98, 953–962 (2015).
Sheikh, Z., Brooks, P. J., Barzilay, O., Fantastic, N. & Glogauer, M. Macrophages, overseas physique large cells and their response to implantable biomaterials. Supplies 8, 5671–5701 (2015).
Wang, F., Gomez-Sintes, R. & Boya, P. Lysosomal membrane permeabilization and cell dying. Site visitors 19, 918–931 (2018).
Franklin, B. S., Mangan, M. S. & Latz, E. Crystal formation in irritation. Annu. Rev. Immunol. 34, 173–202 (2016).
Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
Mulay, S. R. et al. Mitochondria permeability transition versus necroptosis in oxalate-induced AKI. J. Am. Soc. Nephrol. 30, 1857–1869 (2019).
Schauer, C. et al. Aggregated neutrophil extracellular traps restrict irritation by degrading cytokines and chemokines. Nat. Med. 20, 511–517 (2014).
Desai, J. et al. Particles of various dimensions and shapes induce neutrophil necroptosis adopted by the discharge of neutrophil extracellular trap-like chromatin. Sci. Rep. 7, 15003 (2017).
Desai, J. et al. PMA and crystal-induced neutrophil extracellular lure formation includes RIPK1-RIPK3-MLKL signaling. Eur. J. Immunol. 46, 223–229 (2016).
Shi, C. et al. Crystal clots as therapeutic goal in ldl cholesterol crystal embolism. Circ. Res. 126, e37–e52 (2020).
Mulay, S. R. & Anders, H. J. Crystal nephropathies: mechanisms of crystal-induced kidney damage. Nat. Rev. Nephrol. 13, 226–240 (2017).
Worcester, E. M. & Coe, F. L. Medical follow. Calcium kidney stones. N. Engl. J. Med. 363, 954–963 (2010).
Mulay, S. R. & Anders, H. J. Crystallopathies. N. Engl. J. Med. 375, e29 (2016).
Mahajan, A. et al. Frontline science: aggregated neutrophil extracellular traps forestall irritation on the neutrophil-rich ocular floor. J. Leukoc. Biol. 105, 1087–1098 (2019).
Asselman, M., Verhulst, A., De Broe, M. E. & Verkoelen, C. F. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J. Am. Soc. Nephrol 14, 3155–3166 (2003).
Mulay, S. R. et al. Hyperoxaluria requires TNF receptors to provoke crystal adhesion and kidney stone illness. J. Am. Soc. Nephrol. 28, 761–768 (2017).
Cochat, P. & Rumsby, G. Major hyperoxaluria. N. Engl. J. Med. 369, 649–658 (2013).
Kletzmayr, A. et al. Inhibitors of calcium oxalate crystallization for the therapy of oxalate nephropathies. Adv. Sci. 7, 1903337 (2020).
Marschner, J. A. et al. The lengthy pentraxin PTX3 is an endogenous inhibitor of hyperoxaluria-related nephrocalcinosis and persistent kidney illness. Entrance. Immunol. 9, 2173 (2018).
Steiger, S. et al. Anti-transforming progress issue beta IgG elicits a twin impact on calcium oxalate crystallization and progressive nephrocalcinosis-related persistent kidney illness. Entrance. Immunol. 9, 619 (2018).
Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by ldl cholesterol crystals. Nature 464, 1357–1361 (2010).
Mulay, S. R., Evan, A. & Anders, H. J. Molecular mechanisms of crystal-related kidney irritation and damage. Implications for ldl cholesterol embolism, crystalline nephropathies and kidney stone illness. Nephrol. Dialysis Transpl. 29, 507–514 (2014).
Lautenschlager, S. O. S. et al. Plasma proteins and platelets modulate neutrophil clearance of malaria-related hemozoin crystals. Cells https://doi.org/10.3390/cells9010093 (2019).
Kumar, R., Tebben, P. J. & Thompson, J. R. Vitamin D and the kidney. Arch. Biochem. Biophys. 523, 77–86 (2012).
Tebben, P. J., Singh, R. J. & Kumar, R. Vitamin D-mediated hypercalcemia: mechanisms, analysis, and therapy. Endocr. Rev. 37, 521–547 (2016).
Zand, L. & Kumar, R. Using vitamin d metabolites and analogues within the therapy of persistent kidney illness. Endocrinol. Metab. Clin. North. Am. 46, 983–1007 (2017).
Silver, J. & Levi, R. Regulation of PTH synthesis and secretion related to the administration of secondary hyperparathyroidism in persistent kidney illness. Kidney Int. Suppl. 95, S8–S12 (2005).
Silver, J. & Levi, R. Mobile and molecular mechanisms of secondary hyperparathyroidism. Clin. Nephrol. 63, 119–126 (2005).
Lieske, J. C. et al. Renal stone epidemiology in Rochester, Minnesota: an replace. Kidney Int. 69, 760–764 (2006).
Curhan, G. C. Epidemiology of stone illness. Urol. Clin. North. Am. 34, 287–293 (2007).
Curhan, G. C., Rimm, E. B., Willett, W. C. & Stampfer, M. J. Regional variation in nephrolithiasis incidence and prevalence amongst United States males. J. Urol. 151, 838–841 (1994).
Park, S. & Pearle, M. S. Pathophysiology and administration of calcium stones. Urol. Clin. North. Am. 34, 323–334 (2007).
Broadus, A. E. et al. A consideration of the hormonal foundation and phosphate leak speculation of absorptive hypercalciuria. J. Clin. Endocrinol. Metab. 58, 161–169 (1984).
Cupisti, A. et al. Serum calcitriol and dietary protein consumption in idiopathic calcium stone sufferers. Int. J. Clin. Lab. Res. 29, 85–88 (1999).
Frick, Ok. Ok. et al. 1,25(OH)(2)D(3)-enhanced hypercalciuria in genetic hypercalciuric stone-forming rats fed a low-calcium weight-reduction plan. Am. J. Physiol. Ren. Physiol. 305, F1132–F1138 (2013).
Giannini, S. et al. Doable hyperlink between vitamin D and hyperoxaluria in sufferers with renal stone illness. Clin. Sci. 84, 51–54 (1993).
Ketha, H. et al. Altered calcium and vitamin D homeostasis in first-time calcium kidney stone-formers. PLoS One 10, e0137350 (2015).
Lieske, J. C. et al. Stone composition as a perform of age and intercourse. Clin. J. Am. Soc. Nephrol. 9, 2141–2146 (2014).
Singh, P. et al. Stone composition amongst first-time symptomatic kidney stone formers locally. Mayo Clin. Proc. 90, 1356–1365 (2015).
Evan, A., Lingeman, J., Coe, F. L. & Worcester, E. Randall’s plaque: pathogenesis and function in calcium oxalate nephrolithiasis. Kidney Int. 69, 1313–1318 (2006).
Evan, A. P. et al. Randall’s plaque of sufferers with nephrolithiasis begins in basement membranes of skinny loops of Henle. J. Clin. Make investments. 111, 607–616 (2003).
Krambeck, A. E. et al. Present computed tomography strategies can detect duct of Bellini plugging however not Randall’s plaques. Urology 82, 301–306 (2013).
Linnes, M. P. et al. Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. Kidney Int. 84, 818–825 (2013).
Matlaga, B. R., Coe, F. L., Evan, A. P. & Lingeman, J. E. The function of Randall’s plaques within the pathogenesis of calcium stones. J. Urol. 177, 31–38 (2007).
Lieske, J. C., Turner, S. T., Edeh, S. N., Smith, J. A. & Kardia, S. L. Heritability of urinary traits that contribute to nephrolithiasis. Clin. J. Am. Soc. Nephrol. 9, 943–950 (2014).
Lieske, J. C. et al. Heritability of dietary traits that contribute to nephrolithiasis in a cohort of grownup sibships. J. Nephrol. 29, 45–51 (2016).
Lieske, J. C. & Wang, X. Heritable traits that contribute to nephrolithiasis. Urolithiasis 47, 5–10 (2019).
Arcidiacono, T. et al. Idiopathic calcium nephrolithiasis: a overview of pathogenic mechanisms within the mild of genetic research. Am. J. Nephrol. 40, 499–506 (2014).
Gudbjartsson, D. F. et al. Affiliation of variants at UMOD with persistent kidney illness and kidney stones-role of age and comorbid illnesses. PLoS Genet. 6, e1001039 (2010).
Howles, S. A. et al. Genetic variants of calcium and vitamin D metabolism in kidney stone illness. Nat. Commun. 10, 5175 (2019).
Okada, A. et al. Genome-wide evaluation of genes associated to kidney stone formation and elimination within the calcium oxalate nephrolithiasis mannequin mouse: detection of stone-preventive elements and involvement of macrophage exercise. J. Bone Min. Res. 24, 908–924 (2009).
Palsson, R., Indridason, O. S., Edvardsson, V. O. & Oddsson, A. Genetics of frequent advanced kidney stone illness: insights from genome-wide affiliation research. Urolithiasis 47, 11–21 (2019).
Rungroj, N. et al. An entire genome SNP genotyping by DNA microarray and candidate gene affiliation examine for kidney stone illness. BMC Med. Genet. 15, 50 (2014).
Taguchi, Ok. et al. Genome-wide gene expression profiling of Randall’s plaques in calcium oxalate stone formers. J. Am. Soc. Nephrol. 28, 333–347 (2017).
Taguchi, Ok., Yasui, T., Milliner, D. S., Hoppe, B. & Chi, T. Genetic danger elements for idiopathic urolithiasis: a scientific overview of the literature and causal community evaluation. Eur. Urol. Focus 3, 72–81 (2017).
Thorleifsson, G. et al. Sequence variants within the CLDN14 gene affiliate with kidney stones and bone mineral density. Nat. Genet. 41, 926–930 (2009).
Urabe, Y. et al. A genome-wide affiliation examine of nephrolithiasis within the Japanese inhabitants identifies novel inclined Loci at 5q35.3, 7p14.3, and 13q14.1. PLoS Genet. 8, e1002541 (2012).
Vezzoli, G., Terranegra, A., Arcidiacono, T. & Soldati, L. Genetics and calcium nephrolithiasis. Kidney Int. 80, 587–593 (2011).
O’Keeffe, D. T. et al. Medical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: proof of gene dose impact. Osteoporos. Int. 27, 3121–3125 (2016).
Tebben, P. J. et al. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission because of CYP24A1 mutations: results of ketoconazole remedy. J. Clin. Endocrinol. Metab. 97, E423–E427 (2012).
Thompson, B. & Towler, D. A. Arterial calcification and bone physiology: function of the bone-vascular axis. Nat. Rev. Endocrinol. 8, 529–543 (2012).
Leibowitz, J. O. The Historical past of Coronary Coronary heart Illness (Wellcome Institute of the Historical past of Medication, 1970).
Towler, D. A. Commonalities between vasculature and bone: an osseocentric view of arteriosclerosis. Circulation 135, 320–322 (2017).
Stabley, J. N. & Towler, D. A. Arterial calcification in diabetes mellitus: preclinical fashions and translational implications. Arterioscler. Thromb. Vasc. Biol. 37, 205–217 (2017).
Speer, M. Y. et al. Clean muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ. Res. 104, 733–741 (2009).
Bennett, M. R., Sinha, S. & Owens, G. Ok. Vascular clean muscle cells in aherosclerosis. Circ. Res. 118, 692–702 (2016).
Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S. & Oursler, M. J. Regulation of bone formation by osteoclasts includes Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl Acad. Sci. USA 105, 20764–20769 (2008).
Stefater, J. A. third et al. Macrophage Wnt-Calcineurin-Flt1 signaling regulates mouse wound angiogenesis and restore. Blood 121, 2574–2578 (2013).
Demer, L. L. & Tintut, Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler. Thromb. Vasc. Biol. 34, 715–723 (2014).
Cheng, S. L. et al. Focused discount of vascular Msx1 and Msx2 mitigates arteriosclerotic calcification and aortic stiffness in LDLR-deficient mice fed diabetogenic diets. Diabetes 63, 4326–4337 (2014).
Solar, Y. et al. Clean muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ. Res. 111, 543–552 (2012).
Dillon, S., Staines, Ok. A., Millan, J. L. & Farquharson, C. The best way to construct a bone: PHOSPHO1, biomineralization, and past. JBMR 3, e10202 (2019).
Duer, M., Cobb, A. M. & Shanahan, C. M. DNA harm response: a molecular lynchpin within the pathobiology of arteriosclerotic calcification. Arterioscler. Thromb. Vasc. Biol. 40, e193–e202 (2020).
Croft, M. & Siegel, R. M. Past TNF: TNF superfamily cytokines as targets for the therapy of rheumatic illnesses. Nat. Rev. Rheumatol. 13, 217–233 (2017).
Cheng, S. L. et al. Activation of vascular clean muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ. Res. 107, 271–282 (2010).
Jilka, R. L. et al. Decreased oxidative stress and larger bone anabolism within the aged, when in comparison with the younger, murine skeleton with parathyroid hormone administration. Ageing Cell 9, 851–867 (2010).
Behrmann, A. et al. PTH/PTHrP receptor signaling restricts arterial fibrosis in diabetic LDLR(-/-) mice by inhibiting myocardin-related transcription issue relays. Circ. Res. 126, 1363–1378 (2020).
Raison, D. et al. Knockdown of parathyroid hormone associated protein in clean muscle cells alters renal hemodynamics however not blood strain. Am. J. Physiol. Ren. Physiol. 305, F333–F342 (2013).
Yu, N. et al. Elevated mortality and morbidity in gentle main hyperparathyroid sufferers. The Parathyroid Epidemiology and Audit Analysis Examine (PEARS). Clin. Endocrinol. 73, 30–34 (2010).
Nyby, M. D. et al. Desensitization of vascular tissue to parathyroid hormone and parathyroid hormone-related protein. Endocrinology 136, 2497–2504 (1995).
Shao, J. S., Cheng, S. L., Sadhu, J. & Towler, D. A. Irritation and the osteogenic regulation of vascular calcification: a overview and perspective. Hypertension 55, 579–592 (2010).
Zheng, Ok. H. et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in sufferers with aortic stenosis. J. Am. Coll. Cardiol. 73, 2150–2162 (2019).
Elmariah, S. et al. Bisphosphonate use and prevalence of valvular and vascular calcification in ladies MESA (The Multi-Ethnic Examine of Atherosclerosis). J. Am. Coll. Cardiol. 56, 1752–1759 (2010).
Xiang, Z. et al. Focused activation of human Vgamma9Vdelta2-T cells controls Epstein-Barr virus-induced B cell lymphoproliferative illness. Most cancers Cell 26, 565–576 (2014).
Sing, C. W. et al. Affiliation of alendronate and danger of cardiovascular occasions in sufferers with hip fracture. J. Bone Min. Res. 33, 1422–1434 (2018).
Saag, Ok. G. et al. Romosozumab or alendronate for fracture prevention in ladies with osteoporosis. N. Engl. J. Med. 377, 1417–1427 (2017).
Shao, J. S. et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt indicators. J. Clin. Make investments. 115, 1210–1220 (2005).
Krishna, S. M. et al. Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 37, 553–566 (2017).
Shoback, D. et al. Pharmacological administration of osteoporosis in postmenopausal ladies: an endocrine society guideline replace. J. Clin. Endocrinol. Metab. 105, dgaa048 (2020).
Lanske, B. et al. Ablation of the PTHrP gene or the PTH/PTHrP receptor gene results in distinct abnormalities in bone improvement. J. Clin. Make investments. 104, 399–407 (1999).
Gardinier, J. D., Daly-Seiler, C., Rostami, N., Kundal, S. & Zhang, C. Lack of the PTH/PTHrP receptor alongside the osteoblast lineage limits the anabolic response to train. PLoS One 14, e0211076 (2019).
Whyte, M. P. et al. New clarification for autosomal dominant excessive bone mass: mutation of low-density lipoprotein receptor-related protein 6. Bone 127, 228–243 (2019).
Li, C. et al. Disruption of LRP6 in osteoblasts blunts the bone anabolic exercise of PTH. J. Bone Min. Res. 28, 2094–2108 (2013).
Cheng, S. L. et al. Vascular clean muscle LRP6 limits arteriosclerotic calcification in diabetic LDLR-/- mice by restraining noncanonical Wnt indicators. Circ. Res. 117, 142–156 (2015).
Cauley, J. A. Public well being influence of osteoporosis. J. Gerontol. A Biol. Sci. Med. Sci. 68, 1243–1251 (2013).
American Coronary heart Affiliation. Coronary heart and Stroke Statistics. www.coronary heart.org. https://www.coronary heart.org/en/about-us/heart-and-stroke-association-statistics (2020).
Veronese, N. et al. Relationship between low bone mineral density and fractures with incident heart problems: a scientific overview and meta-analysis. J. Bone Min. Res. 32, 1126–1135 (2017).
Chiang, C. H. et al. Hip fracture and danger of acute myocardial infarction: a nationwide examine. J. Bone Min. Res. 28, 404–411 (2013).
Zhou, R., Zhou, H., Cui, M., Chen, L. & Xu, J. The affiliation between aortic calcification and fracture danger in postmenopausal ladies in China: the potential Chongqing osteoporosis examine. PLoS One 9, e93882 (2014).
Szulc, P. et al. Belly aortic calcification and danger of fracture amongst older ladies — the SOF examine. Bone 81, 16–23 (2015).
Chan, J. J. et al. QCT volumetric bone mineral density and vascular and valvular calcification: the Framingham examine. J. Bone Min. Res. 30, 1767–1774 (2015).
Wei, D., Zheng, G., Gao, Y., Guo, J. & Zhang, T. Belly aortic calcification and the chance of bone fractures: a meta-analysis of potential cohort research. J. Bone Min. Metab. 36, 439–446 (2018).
Caffarelli, C., Montagnani, A., Nuti, R. & Gonnelli, S. Bisphosphonates, atherosclerosis and vascular calcification: replace and systematic overview of medical research. Clin. Interv. Ageing 12, 1819–1828 (2017).
Szulc, P., Samelson, E. J., Kiel, D. P. & Delmas, P. D. Elevated bone resorption is related to elevated danger of cardiovascular occasions in males: the MINOS examine. J. Bone Min. Res. 24, 2023–2031 (2009).
Cauley, J. A. et al. Inflammatory markers and the chance of hip and vertebral fractures in males: the osteoporotic fractures in males (MrOS). J. Bone Min. Res. 31, 2129–2138 (2016).
Barbour, Ok. E. et al. Inflammatory markers and danger of hip fracture in older white ladies: the examine of osteoporotic fractures. J. Bone Min. Res. 29, 2057–2064 (2014).
Choi, H. J. et al. Danger of fractures in topics with antihypertensive medicines: a nationwide declare examine. Int. J. Cardiol. 184, 62–67 (2015).
Swanson, C. M. et al. Obstructive sleep apnea and metabolic bone illness: insights into the connection between bone and sleep. J. Bone Min. Res. 30, 199–211 (2015).
Cauley, J. A. et al. Traits of self-reported sleep and the chance of falls and fractures: the Ladies’s Well being Initiative (WHI). J. Bone Min. Res. 34, 464–474 (2019).
Cauley, J. A. et al. Hypoxia throughout sleep and the chance of falls and fractures in older males: the Osteoporotic Fractures in Males Sleep Examine. J. Am. Geriatr. Soc. 62, 1853–1859 (2014).
Sullivan, S. D. et al. Results of self-reported age at nonsurgical menopause on time to first fracture and bone mineral density within the Ladies’s Well being Initiative Observational Examine. Menopause 22, 1035–1044 (2015).
Muka, T. et al. Affiliation of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a scientific overview and meta-analysis. JAMA Cardiol. 1, 767–776 (2016).
D’Amelio, P. et al. Function of iron metabolism and oxidative harm in postmenopausal bone loss. Bone 43, 1010–1015 (2008).
McLean, R. R. et al. Homocysteine as a predictive issue for hip fracture in older individuals. N. Engl. J. Med. 350, 2042–2049 (2004).
Pusceddu, I. et al. Subclinical irritation, telomere shortening, homocysteine, vitamin B6, and mortality: the Ludwigshafen Danger and Cardiovascular Well being Examine. Eur. J. Nutr. 59, 1399–1411 (2019).
Wang, S. et al. Prevalence and extent of calcification over aorta, coronary and carotid arteries in sufferers with rheumatoid arthritis. J. Intern. Med. 266, 445–452 (2009).
Mackey, R. H. et al. Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and heart problems danger within the ladies’s well being initiative. Arthritis Rheumatol. 67, 2311–2322 (2015).
Singh, P., Harris, P. C., Sas, D. J. & Lieske, J. C. The genetics of kidney stone illness and nephrocalcinosis. Nat. Rev. Nephrol. 18, 224–240 (2022).
Mizobuchi, M., Towler, D. & Slatopolsky, E. Vascular calcification: the killer of sufferers with persistent kidney illness. J. Am. Soc. Nephrol. 20, 1453–1464 (2009).